Semaglutide injection pens on display at a news conference in Mumbai. After a key patent expired in March, more than 40 Indian manufacturers launched generic versions of the drug, now available for as little as $8 a month, compared to $349 in the US. | Dhiraj Singh/Bloomberg via Getty Images
By now, Ozempic needs no introduction in America. One in 8 American adults now takes a GLP-1 drug of some kind. But even as millions of people in wealthy countries have benefitted from these drugs, they have remained out of reach for most of the world.
But for a country of 1.4 billion people, this...
HALO NEWSLETTER
Join HALO today and unlock this story instantly — It's Free
